International Bladder Cancer Update 2019 Agenda

Wednesday| JANUARY 23, 2019

11:00 AM – 6:00 PM

3rd International Bladder Cancer Update

Michael S. Cookson, MD, MMHC (Co-Chair)
Daniel P. Petrylak, MD (Co-Chair)

11:00 AM – 2:00 PM

Non-muscle Invasive Bladder Cancer Session

11:00 AM – 11:05 AM Welcome and Introduction
Michael S. Cookson, MD, MMHC
11:05 AM – 11:20 AM Controversies in NMIBC; Guidelines and Beyond
Michael S. Cookson, MD, MMHC
11:20 AM – 11:35 AM Urinary Markers in NMIBC: What’s New?
Sanjay G. Patel, MD
11:35 AM – 11:50 AM T1 Bladder Cancer
Seth P. Lerner, MD
11:50 AM – 12:05 PM BCG Unresponsive Disease
Sanjay G. Patel, MD
12:05 PM – 12:20 PM Enhanced Techniques of NMIBC Detection
Neal D. Shore, MD
12:20 PM – 12:40 PM Panel Discussion/Questions and Answers
12:40 PM– 1:40 PM Educational Lunch Symposium
Speaker: Mark P. Schoenberg, MD
Supported by UroGen Pharma
1:40 PM – 2:00 PM Break and Visit Exhibits
Riverside Foyer
2:00 PM – 3:00 PM

Invasive and Advanced Bladder Session: Part I

2:00 PM – 2:15 PM MIBC Guidelines Review
Michael S. Cookson, MD, MMHC
2:15 PM – 2:30 PM Perioperative Pathways: What We Know Works
Sanjay G. Patel, MD
2:30 PM – 2:45 PM Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns
Seth P. Lerner, MD
2:45 PM – 3:00 PM Panel Discussion/Questions and Answers
3:00 PM – 6:00 PM

Invasive and Advanced Bladder Session: Part II

3:00 PM – 3:20 PM Thromboembolic Complications in Bladder Cancer
Leonard G. Gomella, MD
3:20 PM – 3:40 PM Should Variant Histology Change Management of Bladder Cancer?
Leonard G. Gomella, MD
3:40 PM – 4:00 PM Approaches to the Use of Checkpoint Inhibition Therapy in the Adjuvant/Neoadjuvant Setting
Daniel P. Petrylak, MD
4:00 PM – 4:10 PM Panel Discussion/Questions and Answers
4:10 PM – 4:30 PM Break and Exhibits
Riverside Foyer
4:30 PM – 6:00 PM

Invasive and Advanced Bladder Session: Part III

4:30 PM – 4:45 PM Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard?
Seth P. Lerner, MD
4:45 PM – 5:00 PM PT0 after NAC: Implications for Bladder Sparing and Prognosis
Leonard Gomella, MD
5:00 PM – 5:20 PM Targeted Therapy for the Treatment of Advanced/Metastatic Urothelial Cancer
Daniel P. Petrylak, MD
5:20 PM – 5:40 PM Bladder Cancer and Immunotherapy
Daniel P. Petrylak, MD
5:40 PM – 6:00 PM Panel Discussion/Questions and Answers
6:00 PM – 6:30 PM Break and Exhibits
Riverside Foyer
6:30PM Adjourn
6:30 PM – 8:00 PM IBCU/IPCU/LUGPA Welcome Reception
Upstairs Library

Media Partner:

 

Bladder Cancer Journal

Bladder Cancer is an international multidisciplinary journal published by IOS Press. It facilitates progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal’s Editors-in-Chief are Seth P. Lerner, MD (Baylor College of Medicine, Houston, TX, USA) and Dan Theodorescu, MD, PhD (University of Colorado Cancer Center, Aurora, CO, USA). Included in the quarterly publication are research reports, reviews, short communications, and letters-to-the-editor. In addition, the journal will also have a “News and Views” section for timely commentary. Launched in 2015, the journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the bladder and upper urinary tract.